A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease
Latest Information Update: 13 Aug 2026
At a glance
- Drugs S-337395 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Shionogi
Most Recent Events
- 17 Dec 2025 Status changed from not yet recruiting to recruiting.
- 09 Oct 2025 Status changed from not stated to not yet recruiting.
- 06 Feb 2025 New trial record